

Sandra Vukusic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1119000/publications.pdf>

Version: 2024-02-01

68
papers

11,005
citations

159358

30
h-index

102304

66
g-index

69
all docs

69
docs citations

69
times ranked

9010
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. <i>Lancet Neurology</i> , The, 2018, 17, 162-173.	4.9	4,605
2	Relapses and Progression of Disability in Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2000, 343, 1430-1438.	13.9	1,135
3	Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. <i>Brain</i> , 2003, 126, 770-782.	3.7	839
4	Natural history of multiple sclerosis: a unifying concept. <i>Brain</i> , 2006, 129, 606-616.	3.7	736
5	Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of postpartum relapse. <i>Brain</i> , 2004, 127, 1353-1360.	3.7	573
6	Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults. <i>Neurology</i> , 2018, 90, e1858-e1869.	1.5	401
7	Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. <i>JAMA Neurology</i> , 2020, 77, 1079.	4.5	357
8	Myelin-oligodendrocyte glycoprotein antibody-associated disease. <i>Lancet Neurology</i> , The, 2021, 20, 762-772.	4.9	261
9	MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1719-1731.	1.4	249
10	Objective Evaluation of Multiple Sclerosis Lesion Segmentation using a Data Management and Processing Infrastructure. <i>Scientific Reports</i> , 2018, 8, 13650.	1.6	171
11	Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease. <i>Annals of Neurology</i> , 2021, 89, 30-41.	2.8	123
12	MOG antibody-related disorders: common features and uncommon presentations. <i>Journal of Neurology</i> , 2017, 264, 1945-1955.	1.8	119
13	Multiple sclerosis and pregnancy in the 'treatment era'. <i>Nature Reviews Neurology</i> , 2015, 11, 280-289.	4.9	99
14	Accumulation of irreversible disability in multiple sclerosis: From epidemiology to treatment. <i>Clinical Neurology and Neurosurgery</i> , 2006, 108, 327-332.	0.6	97
15	Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1377-1384.	1.4	89
16	DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1738-1744.	1.7	86
17	Comparative efficacy of fingolimod vs natalizumab. <i>Neurology</i> , 2016, 86, 771-778.	1.5	71
18	Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France. <i>Multiple Sclerosis Journal</i> , 2020, 26, 118-122.	1.4	69

#	ARTICLE	IF	CITATIONS
19	Cranial nerve involvement in patients with MOG antibody-associated disease. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e543.	3.1	53
20	Frequency of myelin oligodendrocyte glycoprotein antibody in multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	49
21	New OFSEP recommendations for MRI assessment of multiple sclerosis patients: Special consideration for gadolinium deposition and frequent acquisitions. <i>Journal of Neuroradiology</i> , 2020, 47, 250-258.	0.6	46
22	Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience. <i>Multiple Sclerosis Journal</i> , 2020, 26, 829-836.	1.4	39
23	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1031-1044.	1.4	39
24	Clinical spectrum of central nervous system myelin oligodendrocyte glycoprotein autoimmunity in adults. <i>Current Opinion in Neurology</i> , 2019, 32, 459-466.	1.8	38
25	Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 936-944.	1.4	37
26	Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. <i>Neurology</i> , 2019, 93, e635-e646.	1.5	36
27	Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France. <i>JAMA Neurology</i> , 2020, 77, 94.	4.5	36
28	Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2021, 20, 1001-1011.	4.9	36
29	Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 953-955.	1.4	35
30	Risk of relapse after natalizumab withdrawal. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e297.	3.1	34
31	Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1543-1555.	1.4	33
32	Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome. <i>JAMA Network Open</i> , 2021, 4, e2128271.	2.8	32
33	Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study. <i>Journal of Neuroinflammation</i> , 2022, 19, 62.	3.1	30
34	Peripheral small fiber dysfunction and neuropathic pain in patients with Morvan syndrome. <i>Neurology</i> , 2015, 85, 2076-2078.	1.5	28
35	Efficacy of rituximab in refractory RRMS. <i>Multiple Sclerosis Journal</i> , 2019, 25, 828-836.	1.4	28
36	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020, 143, 2742-2756.	3.7	24

#	ARTICLE	IF	CITATIONS
37	Diagnostic value of bright spotty lesions on MRI after a first episode of acute myelopathy. <i>Journal of Neuroradiology</i> , 2021, 48, 28-36.	0.6	24
38	Multiple sclerosis lesions segmentation from multiple experts: The MICCAI 2016 challenge dataset. <i>NeuroImage</i> , 2021, 244, 118589.	2.1	23
39	Multiple sclerosis broke my heart. <i>Annals of Neurology</i> , 2017, 81, 754-758.	2.8	22
40	Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1045-1063.	1.4	21
41	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1424-1456.	1.4	16
42	Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e869-e880.	1.5	15
43	Spontaneous multiple cervical artery dissections after alemtuzumab. <i>Multiple Sclerosis Journal</i> , 2020, 26, 381-383.	1.4	14
44	Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. <i>Multiple Sclerosis Journal</i> , 2019, 25, 591-600.	1.4	13
45	Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1155-1159.	1.4	13
46	Weekly enhanced T1-weighted MRI with Gadobutrol injections in MS patients: Is there a signal intensity increase in the dentate nucleus and the globus pallidus?. <i>European Journal of Radiology</i> , 2018, 105, 204-208.	1.2	12
47	Cumulative effects of therapies on disability in relapsing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1760-1770.	1.4	11
48	Effects of Age and Disease Duration on Excess Mortality in Patients With Multiple Sclerosis From a French Nationwide Cohort. <i>Neurology</i> , 2021, 97, e403-e413.	1.5	10
49	Pathologic and MRI analysis in acute atypical inflammatory demyelinating lesions. <i>Journal of Neurology</i> , 2019, 266, 1743-1755.	1.8	9
50	Oral norgestrel acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1458-1463.	1.4	8
51	Untreated patients with multiple sclerosis: A study of French expert centers. <i>European Journal of Neurology</i> , 2021, 28, 2026-2036.	1.7	8
52	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. <i>CNS Drugs</i> , 2021, 35, 1217-1232.	2.7	8
53	MSCopilot: New smartphone-based digital biomarkers correlate with Expanded Disability Status Scale scores in people with Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 55, 103164.	0.9	6
54	Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple Sclerosis. <i>Neurotherapeutics</i> , 2021, 18, 378-386.	2.1	5

#	ARTICLE	IF	CITATIONS
55	Update on brain MRI for the diagnosis and follow-up of MS patients. <i>Presse Medicale</i> , 2021, 50, 104067.	0.8	5
56	Post-partum relapse in women with multiple sclerosis after neuraxial labour analgesia or neuraxial anaesthesia: A multicentre retrospective cohort study. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2021, 40, 100834.	0.6	5
57	Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal. <i>Neurotherapeutics</i> , 2022, 19, 476-490.	2.1	5
58	COPP-MS: Corticosteroids during the Post-Partum in relapsing Multiple Sclerosis patients. <i>Journal of Neurology</i> , 2022, 269, 5571-5581.	1.8	4
59	Clinical significance of a single cerebrospinal fluid immunoglobulin band: A retrospective study. <i>Multiple Sclerosis Journal</i> , 2020, 27, 135245852097822.	1.4	3
60	Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1838-1851.	1.4	3
61	Signal Intensity Evaluation in the Dentate Nucleus and Subcortical Gray Matter. <i>Clinical Neuroradiology</i> , 2022, 32, 677-685.	1.0	3
62	Isolated positive anti-SS-B autoantibodies are not related to clinical features of systemic autoimmune diseases: Results from a routine population survey. <i>PLoS ONE</i> , 2017, 12, e0185104.	1.1	2
63	Rituximab versus fingolimod after natalizumab in multiple sclerosis: Also consider progressive multifocal leukoencephalopathy risk. <i>Annals of Neurology</i> , 2016, 80, 791-791.	2.8	1
64	Where there is inflammation, treatment may reduce disability progression – No. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1810-1812.	1.4	1
65	Unusual neurologic presentation of aseptic abscesses syndrome. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e469.	3.1	1
66	MRI findings in blinded trials should be available to treating physicians – Yes. <i>Multiple Sclerosis Journal</i> , 2021, 27, 812-813.	1.4	1
67	Long-term effect of first-line injectable multiple sclerosis treatments: Input of a time-dependent propensity score. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1680-1688.	0.9	0
68	Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS: Response to the editor. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1610-1611.	1.4	0